Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ApoE mRNA-LNP
- Development stage
- Preclinical
- Lead developer
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
ApoE mRNA-LNP is a lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) encoding apolipoprotein E (APOE). Developed by researchers at The Fifth Affiliated Hospital of Sun Yat-sen University, it is designed for intratesticular delivery to regulate cholesterol metabolism in Leydig cells. By restoring exogenous APOE protein expression, the therapy aims to increase cellular cholesterol uptake and promote testosterone synthesis, offering a potential therapeutic strategy to alleviate late-onset hypogonadism (LOH) and its associated symptoms without causing testicular atrophy.
- Other names
- Apoe-mRNA-LNP
02
Targets
APOE (Apolipoprotein E)
Beyond the preview
Go deeper on ApoE mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ApoE mRNA-LNP.